Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis

Study Overview
=================
Brief Summary
-----------------
We propose to examine several angiogenic/angiostatic mediators in the skin and serum of subjects with SSc and compare it to levels found in the skin and serum of healthy subjects.

Detailed Description
-----------------
Systemic sclerosis (SSc) is a connective tissue disease that is characterized by fibrosis of the skin and internal organs. One of the earliest pathologic changes in patients with SSc is damage to the blood vessels. Many abnormalities have been found in the inner layer of the blood vessel, the enothelial tissue. It is known that there are mediators in the blood and tissues of the body that affect the endothelial tissue. These are called angiogenic (promote blood vessel formation) and angiostatic (inhibit blood vessel formation) mediators. Many of these mediators have been examined in the peripheral blood of patients with SSc, but fewer of these mediators have been examined at the site of action, in the tissue near the microvasculature. We hypothesize that there are differences in the levels of angiogenic/angiostatic mediators between healthy subjects and subjects with SSc. In addition, we propose that there are differences at skin sites that have varying levels of involvement with SSc of these angiogenic/angiostatic factors in subjects with SSc.

Official Title
-----------------
Endostatin and Other Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis

Conditions
-----------------
Systemic Sclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meet American College of Rheumatology criteria for systemic sclerosis Subjects with systemic sclerosis must have involvement proximal to the knee or elbow, excluding the face Persons with no chronic health conditions Exclusion Criteria: Persons with systemic sclerosis as a result of being exposed to chemicals or drugs that can cause a sceroderma-like illness Persons with autoimmune diseases other than systemic sclerosis Persons treated with cyclophosphamide in the last 8 weeks Persons with active infections, including but not limited to hepatitis C, hepatitis B, and HIV Persons prone to bleeding because they are treated with medications that thin the blood or have a low platelet count

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Subjects with diffuse scleroderma | |
| 2<br>Healthy controls | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of endostatin in skin and serum |  | At time of of biopsy and blood draw | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of JAM-A in skin and serum |  | At time of blood draw and skin biopsy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
systemic sclerosis angiogenesis